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Abstract
Thyrotropin-releasing hormone (TRH) activates not only the secretion of thyrotropin (TSH) but also the transcription of TSHb
and a-glycoprotein (aGSU) subunit genes. TSHb expression is maintained by two transcription factors, Pit1 and GATA2, and
is negatively regulated by thyroid hormone (T3). Our prior studies suggest that the main activator of the TSHb gene is
GATA2, not Pit1 or unliganded T3 receptor (TR). In previous studies on the mechanism of TRH-induced activation of the
TSHb gene, the involvements of Pit1 and TR have been investigated, but the role of GATA2 has not been clarified. Using
kidney-derived CV1 cells and pituitary-derived GH3 and TaT1 cells, we demonstrate here that TRH signaling enhances
GATA2-dependent activation of the TSHb promoter and that TRH-induced activity is abolished by amino acid substitution in
the GATA2-Zn finger domain or mutation of GATA-responsive element in the TSHb gene. In CV1 cells transfected with TRH
receptor expression plasmid, GATA2-dependent transactivation of aGSU and endothelin-1 promoters was enhanced by
TRH. In the gel shift assay, TRH signal potentiated the DNA-binding capacity of GATA2. While inhibition by T3 is dominant
over TRH-induced activation, unliganded TR or the putative negative T3-responsive element are not required for TRH-
induced stimulation. Studies using GH3 cells showed that TRH-induced activity of the TSHb promoter depends on protein
kinase C but not the mitogen-activated protein kinase, suggesting that the signaling pathway is different from that in the
prolactin gene. These results indicate that GATA2 is the principal mediator of the TRH signaling pathway in TSHb expression.
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Introduction
The hypothalamus–pituitary–thyroid (H-P-T) axis is the central
mechanism for thyroid hormone (T3) homeostasis [1,2]. Thyro-
tropin (TSH) is a heterodimer of the a chain (a subunit of
glycoprotein hormone, aGSU) and b chain (TSHb). TSHb is
specific to TSH while aGSU is common to luteinizing hormone,
follicle-stimulating hormone and chorionic gonadotropin [3].
Secretion of the TSH molecule from thyrotroph and the
transcriptions of TSHb and aGSU genes are stimulated by the
thyrotropin-releasing hormone (TRH) generated in the hypotha-
lamic paraventricular nucleus. In rat pituitary primary culture, for
example, TRH treatment increases aGSU and TSHb mRNA
[4,5]. Conversely, TSHb expression is attenuated in mice
homologous for a TRH-null allele after birth [6]. TRH receptor
(TRH-R) is encoded by two genes and generates TRH-R1 and 2.
In the pituitary, TRH-R1 but not TRH-R2 is expressed and
mediates the TRH signal [7]. TRH-bound TRH-R1 (TRH/
TRH-R1) induces protein kinase C (PKC)-, phosphophatidyl-
inoshitol- and Ca
2+-mediated pathways [8,9]. PKC subsequently
potentiates multiple transcription factors, including Jun and Fos,
via the AP-1 site [10]; however, the mechanism that mediates
TRH signaling for transcription of the TSHb gene has been
elusive.
A pituitary-specific transcription factor, Pit1, has been postu-
lated to be a candidate mediator of TRH signaling in TSHb gene
regulation. This possibility is supported by the fact that Pit1
mutations cause compound pituitary hormone deficiency (CPHD)
[11], in which expressions of the TSHb gene as well as the
prolactin (PRL) and growth hormone (GH) genes are decreased or
abolished. Using reporter assays with somato-lactotroph-derived
GH3 [12] cells and gel shift assays, Shupnik et al. [13,14] reported
two Pit1 binding sites, TSH-A (nt. 2274/2258) and C (nt. 2402/
2384) while Steinfelder et al. [15,16] demonstrated other putative
Pit1 binding sites within nt. 2128/+8 of the human TSHb gene.
Although Gordon et al. [17] confirmed that Pit1 recognizes the
DNA sequences in the mouse TSHb gene corresponding to those
sites in the rat and human genomes using DNA foot printing,
overexpression of Pit1 had a minimal effect on the activity of the
TSHb promoter in TtT97 TSHoma or thyrotroph-derived aTSH
cells. Similar results were reported with kidney-derived 293 cells
over-expressed with Pit1 [18]. Consistently, TRH treatment does
not enhance transcriptional activity of the fusion protein Gal4-
Pit1, where the Pit1-derived transactivation domain was fused with
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phosphorylated at serine (codon 115) and threonine (codon 220)
by PKA [20] or by TRH signaling [15,16], mutations of these
amino acids have no effect on its transactivation function in the
PRL promoter [19,21].
T3 inhibits transcription of the TSHb gene via thyroid hormone
receptor (TR) [1], and TSHb expression increases in patients with
hypothyroidism. This raises the possibility that unliganded TR
may function as a transcriptional activator of the TSHb gene [22–
24]. Based on this hypothesis, the putative negative T3 responsive
element (nTRE) has been reported as the sequence required for
activation by unliganded TR and inhibition by T3 [22,25].
Because an AP-1-like sequence [26] overlaps with the reported
nTRE, it was suggested that interaction of unliganded TR with
Jun/Fos may play a role in the TRH signaling pathway [27];
however, the findings that TSHb expression can be maintained in
TR-null mice [24,28] rejected the possibility that unliganded TR
is an activator, indicating the presence of another transcriptional
activator [29].
As a TSHb-related transcription factor that exists in TtT97
TSHoma cells but not in GH3 cells, Gordon et al. [30] identified
GATA2. In vivo analysis using transgenic mice revealed that co-
expression of GATA2 with Pit1 directs the differentiation of
thyrotroph in the pituitary [3]. We reported that the true
transcriptional activator for the TSHb gene is GATA2 but not
Pit1 and that Pit1 protects GATA2 from inhibition by the
suppressor region (SR) located in the 39-flanking region of GATA-
REs [31]. We reported that when TR is coexpressed with GATA2
and Pit1, T3-dependent inhibition is easily detected in kidney-
derived CV1 cells [32], which have been used in the studies of
transcriptional activation by T3/TR (positive regulation)
[29,33,34]. Establishment of this experimental system suggests
that thyrotroph-specific factors other than Pit1 and GATA2 may
not be essential for T3-dependent negative regulation of the TSHb
gene [29]. Indeed, repression by T3 was not affected by the
expression of other known cofactors except thyroid receptor-
associated protein (TRAP) 220/MED1 [29,33]. This system
revealed that unliganded TR without Pit1 and GATA2 is not
the activator of the TSHb gene [29]. We found that a putative
nTRE/AP-1-like sequence is dispensable for T3-dependent
inhibition [33] and proposed a model in which T3-bound TR
(T3/TR) interferes with the transactivation function of GATA2,
resulting in negative regulation of the TSHb gene [33]. In this
regard, the role of unliganded TR in the TRH signaling pathway
should be re-considered.
Whereas Charles et al. [35] reported that TSHb expression in
pituitary-specific GATA2 knockout mice was not increased in the
hypothyroid condition, where hypothalamic TRH secretion is
increased, the functional relevance of GATA2 in TRH signaling
was not clarified. To exclude the influence of negative feedback
regulation by T3 on TRH production, we employed reporter
assays in cultured cells. We demonstrate here that GATA2, but
not Pit1 or unliganded TR, is the principal mediator of the TRH
signal in transcriptional activation of the TSHb gene.
Materials and Methods
Plasmid constructions
Because T3/TR has a tendency to suppress the firefly
luciferase-based reporter gene [29,33], we employed the CAT-
and modified Renilla luciferase (hRluc)-based reporter systems
(Promega, Madison, WI, USA). The human TSHb promoters
encompassing nt. 21193/+37 and nt. 2128 to +37 were fused
with the CAT gene, generating TSHb(21193/+37)-CAT and
TSHb(2128/+37)-CAT, respectively [29]. In these reporter
plasmids, the pUC-derived AP-1 site [29], which may mediate
PKC signal, was deleted from the original plasmid [22,26,27].
TSHb-M1-mXmYmZ-CAT, TSHb-M3-CAT, TSHb(2128/
+37)-hRluc and TSHb-mP-M1-hRluc were reported elsewhere
[31,33]. The downstream GATA-RE in TSHb(2128/+37)-hRluc
was mutated from AGATAA to AGATCA using site-directed
mutagenesis (Stratagene, La Jolla, CA), generating TSHb(2128/
+37)-G2C-hRluc. Expression plasmids for human Pit1 (pCB
6-
hPit1), mouse GATA2 (pcDNA3-mGATA2), and the deletion
constructs of GATA2 (GATA2-NZ, GATA2-ZC, and GATA2-Zf)
have been described elsewhere [33]. All mutated sequences and
subcloning sites were confirmed by sequencing.
Cell culture and transient transfection
CV1 [32] and GH3 [12] cells were grown in monolayer culture
at 37 C under CO2/air (1:19) in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% (v/v) fetal calf serum (FCS),
penicillin G (100 units/ml), and streptomycin (100 mg/ml). TaT1
cells, a thyrotroph cell line from the mouse pituitary [36], were
seeded on Matrigel-coated plates (Becton Dickinson Labware,
Bedford, MA, U.S.A.) and maintained under the same conditions
as CV1 and GH3 cells. All cells were trypsinized and plated in 6-
well plates for 24 h before transient transfection. CV1 cells at a
density of 2610
5 cells per well were transfected using the calcium
phosphate technique, as described previously [37]. GH3 and
TaT1 cells at a density of 6610
5 and 3610
5 cells per well were
transfected using lipofectamine reagent (Promega) according to the
manufacturer’s protocol. After cells had been exposed to calcium
phosphate/DNA precipitates or lipofectamine reagent for 20 or
5 h, the medium was replaced with fresh DMEM containing 5%
fetal calf serum depleted of thyroid hormone [37] or medium
supplemented with TRH, tetradecanoylphorbol acetate (TPA) or
forskolin. After incubation for an additional 24 h, cells were
harvested. CAT and b-galactosidase activities were measured as
described previously [37]. Luciferase activities were measured with
the Luciferase Assay System or Renilla Luciferase Assay System
(Promega) using a Lumicounter 700 (Microtech Nichi-on, Chiba,
Japan) [31,33]. Protein concentration was determined by OD280.
For each reporter assay, we performed transfection with pCMV-
CAT, pGL4.13[luc2/SV40], or pGL4.74[hRLuc/TK], the mag-
nitudes of which were adjusted to a value of 100%.
Western blot
To assess the expression level of wild-type GATA2 and C349A
mutant, CV1 cells in a 10 cm dish were transfected with an equal
amount (10 mg/dish) of expression plasmids for wild-type or
mutant GATA2s. After incubation for an additional 24 h, cells
were harvested and whole cell extracts were fractionated by SDS-
PAGE and subjected to Western blot with anti-GATA2 antibody
(a kind gift from Dr. Takashi Minami, University of Tokyo).
Gel shift assay
PG-probe (wild-type TSHb sense; 59-cagtatgaattttcaatagatgctttt-
cagataagaaa-39 and antisense; 59-tttcttatctgaaaagcatctattgaaaatt-
catactg-39) were labeled with c-
32P-ATP using T4 polynucleotide
kinase (Toyobo, Tokyo, Japan). CV1 cells were transfected with
pcDNA3-mGATA2 (5 mg per 10 cm dish). After incubation with
TRH or TPA, cells were harvested. Nuclear extracts (NEs) from
CV1 cells were prepared as described previously [31]. The c-
32P-
labeled probes and 2 mg NEs from transfected CV1 cells were
incubated for 30 min on ice in 20 ml binding buffer containing
10 mM Tris-HCl (pH 7.6), 50 mM KCl, 0.05 mM EDTA,
2.5 mM MgCl2, 8.5% glycerol, 1 mM dithiothreitol, 0.5 mg/ml
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DNA–protein complexes were resolved by electrophoresis on a 5%
polyacrylamide gel at 100 V for 80 min at room temperature. For
the supershift assay, antibodies against GATA2 (SC-267; Santa
Cruz, CA, USA) were added. The gel was dried and labeled bands
were visualized using the BAS-1000 autoradiography system (Fuji
Film, Tokyo, Japan).
Statistical analysis
Each reporter assay was performed in duplicate more than three
times, and each result is expressed as the mean 6 S.D. Statistical
significance was examined by ANOVA and Fisher’s protected least
significant difference test using StatView 4.0 software (Abacus
Concepts, Berkeley, CA, USA). P,0.05 was considered significant.
Results
TRH signaling enhances the transactivation of Pit1 and
GATA2-dependent activity of the TSHb gene in CV1 cells
The human TSHb promoter encompassing nt. 21193/+37 was
fused to the CAT gene to generate TSHb(21193/+37)-CAT
(Fig. 1A). As reported previously [29], co-expression of GATA2
and Pit1 activated TSHb(21193/+37)-CAT in CV1 cells (Fig. 1B,
lane 1 and 2). The TRH-R1 gene generates long (412 aa) and
short (387 aa) isoforms through alternative splicing of pre-mRNA
[8]. In the presence of the long isoform, treatment with 100 nM
TRH showed a further increase of promoter activity (Fig. 1B, lane
3 and 4). As shown in lane 5 and 6, the liganded short isoform
elicited comparable potentiation. Since both TRH-R1s had
similar effects and the long isoform is dominantly expressed in
pituitary tissue [38], we employed it for further studies. It was
reported that, in TtT97 TSHoma cells, the DNA sequence
between nt. 2271/280 in the mouse TSHb promoter (corre-
sponding to sequence nt 2269/278 in the human gene) is
sufficient for maximal promoter activity [39]. As shown in Fig. 1A,
this region harbors a functional Pit1 binding site (Pit1-US) and two
GATA-responsive elements (GATA-REs) [30]. These sequences
are perfectly conserved in rodents and humans. We tested the
effect of TRH/TRH-R1 on TSHb(2128/+37)-CAT, which
contains all of these elements (Fig. 1A), and again found that
GATA2/Pit1-dependent activity (Fig. 1C, lane 1 and 2) was
potentiated by TRH-R1 in the presence of 100 nM TRH (lane 3
and 6), suggesting that the TRH signal can be mediated via the
region, nt 2128/+37, containing Pit1-US and GATA-REs. The
effect of TRH was dose-dependent (lane 3–7).
Effect of TRH/TRH-R1 on Pit/GATA2-dependent activation
of the TSHb promoter is mediated by PKC but not PKA
Activation of the PKC signal by TRH/TRH-R1 is known to
play a critical role in the expression of the PRL gene [9] as well as
the TSHb gene [13]. When CV1 cells were cotransfected with
GATA2 and Pit1, the activity of TSHb(2128/+37)-CAT was
enhanced by the PKC activator, tetradecanoylphorbol acetate
(TPA) (Fig. 1D). Although a cAMP-sensitive region (TSH-B) in the
rat TSHb promoter was reported at nt. 2333/2325 [13], TRH-
induced activity in the presence of Pit1 and GATA2 was
maintained in TSHb(2128/+37)-CAT (Fig. 1C, lane 3 and 4),
which lacks the sequence corresponding to TSH-B (nt 2363/
2355 in the human genome, Fig. 1A). Thus, the stimulatory effect
of TRH via Pit1 and GATA2 is independent of TSH-B. Whereas
the PKA pathway may activate the TSHb promoter via the
interaction of Pit1 with CBP [40], the effect of forskolin on the
Pit1/GATA2-dependent activity of the TSHb gene was much
smaller than that of TPA (Fig. 1D). The putative nTRE [27] in
human TSHb promoter overlaps an AP-1-like sequence (nt. 21/
+6) [26]. To explore the involvement of this sequence in activation
by TRH/TRH-R1, we tested a mutant reporter gene, TSHb-
DX1-CAT [33], where nTRE and AP-1-like sequences were
deleted (Fig. 1A). Transactivation by TRH was not affected in this
construct (Fig. 1E), suggesting that the reported nTRE or AP-1-
like sequence is not required for the activity of the TSHb promoter
when it is stimulated by TRH via Pit1 and GATA2.
TRH signaling potentiates the transactivating function of
GATA2
We reported that the true transcriptional activator of the TSHb
geneisGATA2,whilePit1protectsGATA2functionfrominhibition
bythe suppressor region (SR), whichlocates the 39-flanking region of
GATA-RE (Figs. 1A, 2A) [31]. In accordance with this, GATA2
alone can transactivate the SR-deleted construct, TSHb-M3-CAT
(Fig.2B,lane7).Notably,thisactivitywasenhancedbyTRH/TRH-
R1. An identical result was found with TSHb-M1-mXmYmZ-CAT
(Fig. 2C), which contains only Pit1-US and GATA-REs (Fig. 2A).
This construct was not activated by the mutant GATA2, C349A
(Fig. 2C, inset), the DNA binding activity of which is disrupted [33].
Moreover, C349A was resistant to stimulation by TRH/TRH-R1
(Fig. 2C). The expression level of C349A was comparable with that
of wild-type GATA2 (Fig. 2D). Thus, transactivation by GATA2 is
important for not only basal but also TRH-induced activities of the
TSHb gene. As shown in Fig. 2E (upper panel), GATA-RE was
reported in the endothelin-1 (ET-1) promoter [41]. This promoter
was activated by GATA2 without Pit1 and this activity was
enhanced by TRH/TRH-R1 (Fig. 2E, lower panel). Pit1-indepen-
dent activation was also observed in the human aGSU promoter,
whichhasatypicalGATA-RE[42]andisknowntobestimulatedby
TRH in pituitary primary culture [4] and TPA [43,44]. Because this
promotercontainstwoCREsclosetoGATA-RE,theremaybecross
talk between TRH/TRH-R signaling and PKA pathway. The
GATA2-dependent activity of the human aGSU promoter was
enhanced by the treatment of forskolin in a dose dependent manner
(Fig. 2F). The effect of co-stimulation with forskolin and TRH/
TRH-R had additive but not synergistic effect.
While inhibition by T3/TR is dominant over the activation
by TRH, unliganded TR is not involved in TRH signaling
Using CV1 cells transfected with the expression plasmids for
TRH-R1, GATA2, Pit1 and pituitary-specific TR, TRb2, we
compared the potency of TRH-induced activation with T3/TR-
dependent inhibition in the context of the TSHb promoter. As
shown above (Fig. 1C), 100 nM TRH is sufficient to enhance
transactivation by Pit1 and GATA2, and this concentration is
compatible with the previous reports using pituitary cells [4]. As
we reported previously [29,33,34], T3/TRb2 efficiently inhibited
GATA2/Pit1-dependent transactivation of TSHb(2128/+37)-
CAT stimulated by 100 nM TRH (Fig. 3A). T3/TRb2 also
inhibited TPA-induced activity in the presence of Pit1 and
GATA2 (Fig. 3B). TRH-induced activity of TSHb-M1-
mXmYmZ-CAT (Fig. 2A) with GATA2 was repressed by T3/
TRb2 (Fig. 3C), indicating that inhibition by T3/TRb2i s
dominant over TRH/GATA2-induced activation of the TSHb
promoter. If unliganded TR is a transcriptional activator of the
TSHb gene [22], it might play a role in transcriptional activation
of the TSHb gene by TRH [24,27]. As shown in Fig. 3D,
unliganded TRb2 alone failed to stimulate basal or TRH-induced
activity of the TSHb promoter (lane 1, 2 and 5). Thus, unliganded
TRb2 without Pit1 or GATA2 is not a mediator of TRH signaling
in TSHb gene regulation.
GATA2 Mediates TRH Signaling for TSHb Gene
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18667Figure 1. TRH/TRH-R1 stimulates GATA2/Pit1-dependent activity of the human TSHb gene. (A) Schematics of TSHb(21193/+37)-,
TSHb(2128/+37)- and TSHb-DX1-CAT. Putative TRH-responsive elements (TSH-A, nt. 2274/2258 and TSH-C, nt. 2402/2384) and PKA-sensitive
element (TSH-B, nt. 2333/2325) reported in the rat TSHb gene are indicated as boxes in TSHb(21193/+37)-CAT. Pit1-US, a functional Pit1 binding
site upstream of GATA-REs. GATA-REs, GATA responsive elements. SR, suppressor region. (B) and (C) Two mg TSHb(21193/+37)-CAT (B) or
TSHb(2128/+37)-CAT (C) was cotransfected into CV1 cells together with the expression plasmids for Pit1 (0.1 mg), GATA2 (0.2 mg), TRH-R1(412) or
TRH-R1(387) (0.2 mg) and b-galactosidase-based reporter gene (pCH111, 1.1 mg). After 24h of culture, the cells were treated with 1–1000 nM TRH. (D)
TPA, but not forskolin, enhances the Pit1/GATA2-dependent activity of TSHb(2128/+37)-CAT. CV1 cells were cotransfected with 2.0 mgo f
TSHb(2128/+37)-CAT together with the expression plasmids for Pit1 (0.1 mg), GATA2 (0.2 mg), TRH-R1 (0.2 mg; 412 aa or 387 aa) and pCH111 (1.1 mg).
After 24h of culture, the cells were treated with 1–100 nM TPA or 1–100 mM forskolin. (E) AP-1-like sequence overlapping with putative nTRE is
dispensable for TRH-induced activation of the TSHb gene. Reporter assay with TSHb-DX1-CAT was performed as described in (C). CAT activity was
normalized with b-galactosidase activity. CAT activity for pCMV-CAT (5 ng/well) was taken as 100%. Data are expressed as the mean 6 S.D. of at least
three independent experiments. *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0018667.g001
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18667Figure 2. GATA2 alone mediates TRH signaling for transcription of the SR-less TSHb promoter. (A) Schematics of TSHb(2128/+37)-CAT,
TSHb-M3-CAT and TSHb-M1-mXmYmZ-CAT. SR was deleted in both constructs and AP-1-like sequence/nTRE was mutated in TSHb-M1-mXmYmZ-
CAT. (B) and (C) Two mg TSHb(2128/+37)-CAT, TSHb-M3-CAT (B) and TSHb-M1-mXmYmZ-CAT (C) were transfected into CV1 cells along with the
expression plasmids for Pit1 (0.1 mg), GATA2 (0.2 mg), TRH-R1(412) (0.2 mg), and pCH111 (1.1 mg) in the presence or absence of 100 nM TRH. Basal and
TRH-induced activities of TSHb-M1-mXmYmZ-CAT were abolished with mutant GATA2, C349A (inset). (D) Expression level of wild-type GATA2 and
C349A mutant. CV1 cells in 10 cm dish were transfected with an equal amount (10 mg/dish) of expression plasmids for wild-type or mutant GATA2s.
Whole cell extracts were fractionated by SDS-PAGE and subjected to Western blot with anti-GATA2 antibody. (E) Schematic representation of hET1-
CAT (upper panel). Two mg of hET1-CAT was transfected into CV1 cells along with expression plasmids for GATA2 (0.2 mg), TRH-R1(412) (0.2 mg), and
pCH111 (1.1 mg) in the presence or absence of 100 nM TRH (lower panel). (F) Schematic representation of haGSU-CAT (upper panel). Reporter assay
was carried out as described in (E) in the presence or absence of 0–10 mM forskolin (lower panel). CAT activity was normalized with b-galactosidase
activity. CAT activity for pCMV-CAT (5 ng/well) was taken as 100%. Data are expressed as the mean 6 S.D. of at least three independent experiments.
*, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0018667.g002
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mediating TRH signaling
The Zn finger domain of GATA2 (GATA2-Zf) has high
sequence homology with those of GATA1 and 3 (Fig. 4A, left
panel) and GATA3 partially compensates for GATA2 in pituitary-
specific GATA2-knockout mice [35]. As shown in Fig. 4B, TPA
enhanced the transactivation of TSHb-M1-mXmYmZ-CAT
(Fig. 2A) by GATA2 as well as GATA1 and 3 without Pit1.
While TRH signaling was abolished by the mutation (C349A) in
GATA2-Zf (Fig. 2C), the transcriptional activity of the deletion
constructs that lack the N- or C-terminal region of GATA2
(Fig 4A, right panel) was significantly stimulated by TPA (Fig. 4C),
showing that GATA2-Zf is important for the activation by TRH/
PKC signaling. Although phosphorylation of serine residue at
codon 401 in human GATA2 was reported to increase its nuclear
localization [45], substitution of the serines at codon 401 and 402
in the mouse GATA2 (Fig. 4A, left panel) with alanines did not
affect the response to TPA (Fig. 4D). As shown in Fig. 4E, TPA
(10 nM) treatment did not alter the molecular weight of FLAG-
tagged GATA2-Zf expressed in CV1 cells.
TRH signaling facilitates the DNA binding capacity of
GATA2
Because GATA2-Zf functions as an interface to recognize
GATA-REs, we performed a gel shift assay to assess the effect of
TRH on DNA binding of GATA2-Zf. CV1 cells were co-
transfected with TRH-R1 and GATA2, and cultured with or
without 100 nM TRH. The nuclear extracts were incubated with
32P-labeled DNA fragment harboring two GATA-REs in the
TSHb promoter (Fig. 5A). As we reported [31], two bands
corresponding to GATA2 monomer and dimer were observed
(Fig. 5B, lane 2). Interestingly, these bands were potentiated by
TRH treatment (lane 3). These signals were abolished by the 50-
fold specific competitor (lane 4) but not unrelated DNA (lane 5)
and supershifted by a specific antibody against GATA2 (lane 6).
Identical results were obtained in the nuclear extract from CV1
Figure 3. Negative regulation by T3/TRb2 is dominant over the transcriptional activation induced by TRH/TRH-R1 or TPA. (A) and (B)
Two mg TSHb(2128/+37)-CAT was transfected into CV1 cells along with expression plasmids for Pit1 (0.1 mg), GATA2 (0.2 mg), TRH-R1(412) (0.2 mg),
TRb2 (0.2 mg) and pCH111 (1.1 mg). After 24 h of culture, the cells were treated with 100 nM TRH (A) or 10 nM TPA (B) for an additional 24 h in the
presence or absence of 1–1000 nM T3. (C) Two mg TSHb-M1-mXmYmZ-CAT (Fig. 2A) was transfected into CV1 cells along with expression plasmids for
GATA2 (0.2 mg), TRH-R1(412) (0.2 mg), TRb2 (0.2 mg), and pCH111 (1.1 mg). After 24 h of culture, the cells were treated with 100 nM TRH for an
additional 24 h in the presence or absence of 1–1000 nM T3. (D) Unliganded TRb2 alone does not mediate TRH signaling. TSHb(2128/+37)-CAT and
expression plasmids for human TRb2 (0.2 mg), TRH-R1(412) (0.2 mg), and pCH111 b(1.1 mg) were transfected into CV1 cells along with or without the
expression plasmids for Pit1 (0.1 mg) and GATA2 (0.2 mg). After 24 h of culture, the cells were treated with 100 nM TRH and/or 1000 nM T3 for an
additional 24 h. CAT activity was normalized with b-galactosidase activity. CAT activity for pCMV-CAT (5 ng/well) was taken as 100%. Data are
expressed as the mean 6 S.D. of three independent experiments. *, P,0.05; **, P,0.01, ***, P,0.001.
doi:10.1371/journal.pone.0018667.g003
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in CV1 cells was not affected by treatment with TRH or TPA
(Fig. 5D). Collectively, TRH/PKC signal facilitates the DNA
binding of GATA2 in the TSHb promoter.
TRH signaling in somato-lactotroph cell line, GH3,
transfected with GATA2 gene
GH3 is a somato-lactotroph cell line expressing endogenous
TRH-R1(412) [8] and Pit1 but not GATA2 [30]. In this regard,
GH3 cells provide a suitable experimental system to explore
the function of GATA2. Because of the low transfection efficiency
of GH3 cells, we fused the hRluc-based reporter gene with
human TSHb promoters to generate TSHb(21193/+37)- or
TSHb(2128/+37)-hRluc (Fig. 6A). Although GH3 cells express
endogenous Pit1, the transcriptional activity of TSHb(21193/
+37)-hRluc was very low (Fig. 6B, lane 1), presumably due to the
lack of GATA2. While TRH treatment modestly activated the
TSHb promoter in GH3 cells via endogenous TRH-R1 (lane 2)
Figure 4. GATA2-Zf mediates TRH/PKC signaling for the TSHb promoter. (A) Schematics of full-length GATA2, GATA1, GATA3, GATA2-NZ, ZC
and Zf. Homology of amino acids between GATA3 and 1 relative to GATA2 is indicated as a percentage in boxes. (B) and (C) TSHb-M1-mXmYmZ-CAT
(2.0 mg, Fig. 2A), and pCH111 (1.1 mg) were cotransfected into CV1 cells with various GATA2 mutants (0.2 mg) with or without 10 nM TPA (left panel).
CAT activity was normalized with b-galactosidase activity. (D) Alanine substitutions with serines at codons 401 or 402 in mouse GATA2-Zf did not
affect TRH-induced activation. Reporter assay was carried out as described in (B) and (C). CAT activity for pCMV-CAT (5 ng/well) was taken as 100%.
The fold activation (right panel) was calculated from CAT activity with TPA divided by that without TPA. ND, not determined. Data are expressed as
the mean 6 S.D. of at least three independent experiments. **, P,0.01; ***, P,0.001. (E) CV1 cells were cotransfected with FLAG-tagged GATA2
expression plasmid and were treated with 10 nM TPA. Whole cell extracts were resolved by SDS/PAGE and western blot analyses for GATA2-Zf and b-
actin were performed using the anti-FLAG and anti-b-actin antibodies, respectively.
doi:10.1371/journal.pone.0018667.g004
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enhanced by TRH treatment (lane 3 and 4). In TSHb(2128/
+37)-hRluc, GATA2-dependent activation was also potentiated by
TRH (Fig. 6C, lane 3 and 4). Although disruption of Pit1-US is
known to abolish the activity of the TSHb promoter [31,46],
deletion of SR enables GATA2 to re-activate transcription without
Pit1 [31]. As predicted, TRH-induced GATA2 activity was
maintained in TSHb-mP-M1-hRluc, where Pit1-US was mutated
and SR was deleted (Fig. 6A and D). In TSHb(2128/+37)-hRluc,
TRH induced some activity without co-expression of GATA2
(Fig. 6C, lane 1 and 2), but Pit1 is unlikely to mediate this activity
since similar TRH-induced activity was observed in TSHb-mP-
M1-hRluc (Fig. 6D), where a functional Pit binding site, Pit1-US,
was mutated. These results suggest again that Pit1 is not the direct
target of TRH signaling.
TRH/GATA2-induced transactivation of TSHb gene is
independent of MAPK signaling
As shown in Fig. 6E, a PKC inhibitor, staurosporin, reduced the
TRH-induced activity of TSHb(2128/+37)-hRluc in GH3 cells
co-transfected with GATA2. In this cell line, PKC is known to
stimulate the mitogen-activated protein kinase (MAPK) pathway
[9], resulting in activation of the PRL promoter via the Ets family
transcription factor [47]. Consistently, TRH treatment stimulated
the activity of PRL-Luc, where the PRL promoter was fused with
the luciferase gene (Fig. 6F). We speculated that the role of MAPK
may be different between the TSHb gene and the PRL gene if
TRH signaling in the former gene is mediated by GATA2 but not
Ets. While MAPK inhibitors, U0126 and SB202190, abolished the
stimulatory effect of TRH on PRL-Luc (Fig. 6F), the TRH-
induced activity of GATA2 in TSHb(2128/+37)-hRluc was
resistant to these compounds (Fig. 6G). Similar results were
observed when we used a c-Jun N-terminal kinase inhibitor,
SP600125 (data not shown).
GATA2 is the limiting factor for the TRH signaling in
thyrotroph cell line, TaT1
TaT1 cells were regarded as a thyrotroph cell line [48] and
reported to express endogenous Pit1, TRb2 [36] and (presumably)
TRH-R[49]. Westernblotting with anti-GATA2antibody revealed
that the expression level of GATA2 in this cell line is low and similar
to that in Hela cells (Fig. 7A)[50]. We previously found that, in Hela
cells, co-expression of GATA2 as well as Pit1 was required for the
reporter assay with TSHb(2128/+37)-CAT (data not shown). In a
reporter assay with TSHb(2128/+37)-hRluc (Fig. 7B) in TaT1
cells, the effect of 100 nM TRH treatment exhibited minimal
induction (Fig. 7C, lane 2) and transient transfection of GATA2
permitted significant enhancement by TRH (Fig. 7C, lane 3 and 4).
This suggested that GATA2 is a limiting factor for TRH signaling.
We tested TSHb-G2C-hRluc, where downstream GATA-RE was
mutated (Fig. 7B). Although this construct harbors intact Pit1-US,
induction by TRH was abolished (Fig. 7C, lane 7 and 8), suggesting
that GATA2 is essential for TRH-induced activation of the TSHb
gene in TaT1 cells.
Figure 5. Treatment with TRH and TPA enhance DNA binding of GATA2. (A) Schematic of probe-PG that has two GATA-REs. (B) and (C) CV1
cells were cotransfected with GATA2 and TRH-R1(412) expression plasmids and were treated with 100 nM TRH (B) or 10 nM TPA (C). NE from CV1 cells
(2 mg) was incubated with c-
32P-labeled probe-PG. DNA-protein complexes were resolved by electrophoresis on a 5% polyacrylamide gel. Solid
arrowhead, GATA2 monomer; open arrowhead, GATA2 dimer. Solid and open arrows on the right indicate the supershifts of GATA2 monomer and
dimer, respectively. Ab, anti-GATA2 antibody; PG, cold probe-PG; NS, non-specific oligonucleotide; free, free radiolabeled probe-PG. (D) Western blot
analysis was performed using the anti-GATA2 antibody. NEs of CV1 cells (10 mg) described in (B) and (C) were resolved by SDS/PAGE (10% gel).
Molecular weight markers are shown on the left.
doi:10.1371/journal.pone.0018667.g005
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PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18667Figure 6. Pit1-US is dispensable for TRH signaling in the SR-less TSHb promoter in pituitary-derived GH3 cells transfected with
GATA2. (A) Schematics of TSHb(21193/+37)-hRluc, TSHb(2128/+37)-hRluc, and TSHb-mP-M1-hRluc. In TSHb-mP-M1-hRluc, Pit1-US was mutated
and SR was deleted. (B) and (C) Co-transfection of GATA2 allows TRH/TRH-R1 to activate TSHb(21193/+37)-hRluc (B) and TSHb(2128/+37)-hRluc (C).
(D) Although Pit1-US is mutated in TSHb-mP-M1-hRluc, deletion of SR enabled GATA2 to activate transcription. Using lipofection, 0.4 mg
TSHb(21193/+37)-hRluc (B), TSHb(2128/+37)-hRluc (C), or TSHb-mP-M1-hRluc (D) was cotransfected into GH3 cells together with the expression
plasmid for GATA2 (0.05 mg) and pGL4.13[luc2/SV40] (0.05 mg). After 5 h of culture, the cells were treated with 100 nM TRH for 12 h. hRluc activity
was normalized with firefly luciferase activity of pGL4.13[luc2/SV40]. (E) GH3 cells were cotransfected with TSHb(2128/+37)-hRluc (0.45 mg) and
GATA2 expression plasmid (0.05 mg). After 5 h culture, cells were treated with 100 nM TRH for 12 h in the presence or absence of PKC inhibitor,
staurosporin (5–100 nM). hRluc activity was normalized with protein concentration. (F) GH3 cells were cotransfected with PRL-luc plasmid (0.5 mg)
and treated with 100 nM TRH for 12 h with or without MAPK inhibitor, U0126 (5–10 mM) or SB202190 (50–100 mM). Firefly luciferase activity was
normalized with protein concentration. (G) TRH/GATA2-induced activation of the TSHb promoter depends on PKC but not MAPK in GH3 cells. GH3
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We reported previously that the true transcriptional activator
of the TSHb gene is GATA2, not Pit1 [31] or unliganded TR
[29]. Here, we demonstrated that GATA2 is the principal
mediator of TRH signaling for TSHb expression. TRH-induced
activity is abolished by amino acid substitution in the GATA2-Zn
finger domain (C349A, Fig. 2C). TRH signal stimulates GATA2-
dependent activities of the aGSU gene and the ET-1 gene (Fig. 2E
and F). In agreement with previous reports [17–19], the current
work provides additional lines of evidence that the Pit1 or Pit1-
CBP/p300 complex is not the main target of TRH signaling.
First, GATA2 is sufficient and Pit1 is dispensable for TRH-
induced activation of the TSHb promoter when SR was deleted
(Fig. 2B and 6D). Second, Pit1 in TaT1 cells [36] failed to
mediate the TRH signal in TSHb-G2C-hRluc, which has intact
Pit1-US but harbors a mutation in GATA-RE (Fig. 7B and C).
Third, although Pit1 may be phosphorylated [15,16,20], sub-
stitution of candidate amino acids with alanines did not affect
transcriptional activity of the TSHb gene (data not shown), as in
the PRL gene [21,47]. We reported that the function of Pit1 does
not have conventional synergism with GATA2, but rather
protects GATA2 function from SR-induced suppression (de-
repression).
Kim et al. [49] reported that the TRH signal may induce the
expression of a transcription factor, Lhx2, in TaT1 cells. According
to the authors, Lhx2 subsequently binds the DNA sequence (nt.
286/268 in the rat TSHb gene) that overlaps with SR, and
activates the TSHb promoter even in aTSH cells, which lack
endogenous Pit1 [17,49]; however, their findings were not
compatible with reduced TSHb expression in a CPHD patient
with mutant Pit1 [11]. Although they reported that Lhx2 also
activates the TSHb promoter in GH3 cells, which lacks endogenous
GATA2, this does not agree with our finding that the mutation of
GATA-RE abolished the transactivation by TRH in TaT1 cells
(Fig. 7C). We could not detect the activation of the human TSHb
promoter (TSHb(2128/+37)-CAT) by co-transfection of the Lhx2
expression plasmid into CV1 cells (data not shown).
TRH/TRH-R-induced PKC activity is known to stimulate
MAPK activity [9,51] and MAPK subsequently phosphorylates
Ets transcription factors and activates the PRL gene [47]. Of note,
phosphorylation by MAPK does not affect the functions of
GATA2 [52] and the transactivation domain of Pit1 [53]. The
current study using GH3 cells transfected with GATA2 indicates
that TRH/GATA2/Pit1-induced activation of the TSHb pro-
moter depends on PKC (Fig. 6E) but not MAPK (Fig. 6G). To our
knowledge, this is the first report showing the difference in the
TRH signaling pathway between the TSHb gene and the PRL
Figure 7. GATA2 is a limiting factor for TRH-induced transactivation of the TSHb gene in TaT1 cells. (A) Expression of endogenous
GATA2 in thyrotroph-derived cell line, TaT1 is comparable with that of Hela cells. Whole cell extracts of CV1 cells transfected with GATA2 expression
plasmid (lane 1), TaT1 cells (lane 2) and Hela cells (lane 3) were fractionated by SDS-PAGE and subjected to Western blot with anti-GATA2 antibody.
(B) Schematic representations of TSHb(2128/+37)-hRluc and TSHb(2128/+37)-G2C-hRluc. Downstream GATA-RE was mutated in TSHb(2128/+37)-
G2C-hRluc. (C) Co-transfection of GATA2 enables TRH to activate the TSHb promoter (lane 1–4). GATA2-dependent as well as TRH-induced
transcriptional activations were abolished by the mutation of GATA-RE (lane 5–8). TaT1 cells were cotransfected with TSHb(2128/+37)-hRluc
(0.45 mg) or TSHb(2128/+37)-G2C-hRluc along with GATA2 expression plasmid (0.05 mg). After 5 h culture, the cells were treated with 100 nM TRH for
12 h. hRluc activity was normalized with the activity of pCMV-bgal. The magnitude of hRluc activity for pGL4.74 [hRLuc/TK] (50 ng/well) was taken as
100%. Data are expressed as the mean 6 S.D. of at least three independent experiments. ***, P,0.005.
doi:10.1371/journal.pone.0018667.g007
cells were cotransfected as described in (E). After 5 h culture, the cells were treated with 100 nM TRH for 12 h with or without U0126 (5–10 mM), or
SB202190 (50–100 mM). The magnitude of hRluc activity for pGL4.74 [hRLuc/TK] or firefly luciferase activity for pGL4.13 [luc2/SV40] (50 ng/well) was
taken as 100%. Data are expressed as the mean 6 S.D. of at least three independent experiments. U, U0126; SB, SB202190; *, P,0.05; **, P,0.01;
***, P,0.001.
doi:10.1371/journal.pone.0018667.g006
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and Pit1-CBP/p300 complex plays a role in TSHb expression
[23,31,40], activation of GATA2 by TRH is independent of the
PKA pathway because transactivation of the TSHb promoter in
the presence of Pit1 and GATA2 was not enhanced by forskolin
(Fig. 1D) or did not require a putative cAMP-sensitive site, TSH-B
(Fig. 1C). This is in agreement with previous in vivo studies
[8,51,54,55].
GATA2-NZ and ZC partially mediate TRH-induced transacti-
vation (Fig. 4C) while mutation of GATA2 (C349A) abolished it
Figure 8. Mechanism of TRH-induced transactivation of the TSHb gene. (A) GATA2 plays a pivotal role in both TRH-induced activation as
well as T3/TR-dependent inhibition. Unlike the PRL gene, transactivation of the TSHb gene is independent of the MAPK pathway. Pit1 competes the
binding of SR binding protein and protects the function of GATA2 from inhibition and also binds to Pit1-US to cooperate with GATA2s to recruit a
coactivator, CBP/p300. PIC, pre-initiation complex. Pol II, RNA polymerase II. (B) Roles of GATA2, Pit1 and TR in hypo- and hyper-thyroidism. Co-
expression of GATA2 and Pit1 determines thyrotroph differentiation. With support by Pit1, GATA2 maintains the basal transcription of the TSHb gene
and mediates TRH/TRH-R1 signaling in hypothyroidism while unliganded TR alone is not a transcriptional activator. Inhibition by T3/TR is dominant
over the activation by GATA2 even in the presence of TRH signaling.
doi:10.1371/journal.pone.0018667.g008
GATA2 Mediates TRH Signaling for TSHb Gene
PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e18667(Fig. 2C), suggesting the crucial role of GATA2-Zf in TRH
signaling. Although the detailed mechanism of how GATA2-Zf
mediates TRH signaling is unknown, there are the following
possibilities. First, stimulation by TRH/TRH-R1 or TPA
enhanced the DNA binding capacity of GATA2, as shown in
our gel shift assay (Fig. 5). Similar effects of PKC were reported in
the GATA-REs of vascular adhesion molecule-1 promoter [56]
and in the human aGSU gene [43]. Second, phosphorylation of
serine at codon 401 in GATA2-Zf (Fig. 4A) may facilitate the
nuclear localization of GATA2 [45]. In our experimental
condition, however, the substitution of serines at codon 401 or
402 with alanines did not cripple the TPA effect (Fig. 4D). As
reported previously [57], the effect of the phosphorylation of these
serine residues may be specific to the promoter context. Finally,
TRAP220/MED1 plays an important role (Fig. 8A). TSHb
expression was reduced in heterozygous TRAP220/MED1-
deficient mice [58] and GATA2-Zf interacted with TRAP220/
MED1 [59]. Our preliminary data showed that GATA2-
dependent activation of the TSHb promoter by TRH signaling
is also mediated by TRAP220/MED1 (data not shown). Because
TRAP220/MED1 contains multiple amino acid sequences which
can be phosphorylated by various kinases, including PKC [60,61],
its phosphorylation may be involved in the TRH signaling
pathway.
Unexpectedly, we found that the GATA2 expression level in
TaT1 cells is insufficient for TRH-induced activation (Fig. 7C)
and failed to detect in vivo binding of GATA2 to the TSHb
promoter in this cell line (data not shown). Although TaT1 was
established from transgenic mice harboring SV40-large T antigen
fused with the aGSU promoter [36,48], high and sustained
expression of GATA2 may increase the amount of SV40-large T
antigen (Fig. 2F), resulting in phenotype alteration with limited
GATA2 expression. Forced expression of GATA2 in TaT1 cells
enabled the wild-type TSHb gene to be activated by TRH
stimulation (Fig. 7C, left panel), indicating that GATA2 is a
limiting factor for the TRH signaling in this cell line.
Although genetic ablation of H-P-T axis-related genes has been
tested [24,28,62] and pituitary-specific GATA2-knockout mice
established [35], the relative contributions of TRH signaling and
negative feedback by T3 in TSHb expression have not been
clarified at the molecular level. We found that T3/TRb2
rigorously inhibits GATA2-dependent activity enhanced by
TRH or TPA (Fig. 3), suggesting that, with high T3 concentration,
repression by T3/TR is dominant over the effect of TRH
signaling (Fig. 8B). This is compatible with the recent report
comparing Pax8-null mice with Pax8/TRH-R1 double knockout
mice [62] and the previous study that administration of TRH
failed to stimulate TSHb synthesis in a subject with overt
thyrotoxicosis [63]. Our prior report suggests that T3-dependent
interaction of TR with TRAP220/MED1 may interfere with the
function of GATA2 [33] (Fig. 8A). TRAP220/MED1 is a
constituent of the Mediator complex that directly regulates the
function of RNA polymerase II (pol II) [64]. Given that inhibition
by T3 targets the final process of GATA2-induced transactivation,
i.e. TRAP220/MED1-pol II complex, repression might occur
downstream of or in the same step as TRH-induced activation.
It should be noted that release of the suppression by T3/TR is
necessary but not sufficient for TSHb expression. In hypothyroid-
ism, the majority of TRb2 in thyrotroph is unliganded and TRH
production in the hypothalamus is increased [65] (Fig. 8B).
Nikrodhanond et al. [24] compared TSH production among wild-
type, TRb-knockout and TRH/TRb-double knockout mice under
hypothyroid conditions and made two important findings. First,
TRb-knockout mice and wild-type mice exhibited comparable
TSHb expression in hypothyroidism where TRH secretion from
the hypothalamus is elevated [65]. This supports our finding that
unliganded TRb is not essential for TRH-induced TSHb
expression (Fig. 3D, lane 2 and 5). Second, TSH level in
hypothyroidism was severely impaired in TRH/TRb-double
knockout mice compared with wild-type or TRb-knockout mice,
suggesting that elevation of TSHb expression requires the TRH
signal even when inhibition by T3/TR is released (Fig. 8B). We
found here that the factor mediating TRH signal for TSHb
expression is GATA2 (Fig. 2C, 3D and 7C). This is supported by
the report that pituitary-specific GATA2-knockout mice exhibit
reduced TSHb expression in hypothyroidism, where stimulation
by TRH should be elevated [35]. As shown in Fig. 8B, GATA2
mediates not only the negative regulation by T3/TR [33] but also
TRH-induced activation of the TSHb gene.
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